NCT04178070 - Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

April 30, 2021

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

GB224 2mg

2mg (100μL), single dose, abdominal subcutaneous injection

BIOLOGICAL

GB224 5mg

5mg (250μL), single dose, abdominal subcutaneous injection

BIOLOGICAL

GB224 10mg

10mg (500μL), single dose, abdominal subcutaneous injection

BIOLOGICAL

GB224 15mg

15mg (750μL), single dose, abdominal subcutaneous injection

BIOLOGICAL

GB224 20mg

20mg (1mL), single dose, abdominal subcutaneous injection

BIOLOGICAL

GB224 30mg

30mg (1.5mL), single dose, abdominal subcutaneous injection

OTHER

Placebo, 2mg

2mg (100μL), single dose, abdominal subcutaneous injection

OTHER

Placebo, 5mg

5mg (250μL), single dose, abdominal subcutaneous injection

OTHER

Placebo, 10mg

10mg (500μL), single dose, abdominal subcutaneous injection

OTHER

Placebo, 15mg

15mg (750μL), single dose, abdominal subcutaneous injection

OTHER

Placebo, 20mg

20mg (1mL), single dose, abdominal subcutaneous injection

OTHER

Placebo, 30mg

30mg (1.5mL), single dose, abdominal subcutaneous injection

Trial Locations (1)

100191

RECRUITING

Peking University People's Hospital, Beijing